| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer
1 company
Mai-Britt Zocca last filed a Form 4 in April 2025, as Chief Executive Officer at IOBT. Mai-Britt Zocca's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 49,891 shares of IOBT. Net of sales, the IOBT filings show accumulation of 12,500 shares.
Mai-Britt Zocca has 7 Form 4 filings on record from November 2021 to April 2025, all as Chief Executive Officer at IO Biotech (IOBT), 2021–2025.
The 8 reported transactions were 5 option or other derivative awards, 1 open-market purchase, 1 stock award and 1 conversion.
Counted by filing, the open-market trades come to 1 purchase worth about $10K and no sales.
The only open-market purchase was 12,500 shares of IOBT at an average $0.81 on December 23, 2024, about $10K. Twelve months later IOBT was down 21%.
Shares as reported in the last Form 4 for each company; the most recent is from April 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 23, 2024 | IOBT Io Biotech, Inc. | Chief Executive Officer | Buy | 12,500 | $0.81 | $10,120.00 | +33.4% | +12.4% | -21.3% |